Reversing multidrug resistance by tyrosine kinase inhibitors
- PMID: 22237041
- PMCID: PMC3777484
- DOI: 10.5732/cjc.011.10315
Reversing multidrug resistance by tyrosine kinase inhibitors
Abstract
Recently, a large number of tyrosine kinase inhibitors(TKIs) have been developed as anticancer agents. These TKIs can specifically and selectively inhibit tumor cell growth and metastasis by targeting various tyrosine kinases and thereby interfering with cellular signaling pathways. The therapeutic potential of TKIs has been hindered by multidrug resistance(MDR), which is commonly caused by overexpression of ATP-binding cassette(ABC) membrane transporters. Interestingly, some TKIs have also been found to reverse MDR by directly inhibiting the function of ABC transporters and enhancing the efficacy of conventional chemotherapeutic drugs. In this review, we discuss ABC transporter-mediated MDR to TKIs and MDR reversal by TKIs.
Similar articles
-
Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.Curr Drug Metab. 2010 Sep;11(7):618-28. doi: 10.2174/138920010792927316. Curr Drug Metab. 2010. PMID: 20812904 Review.
-
Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Molecules. 2014 Sep 4;19(9):13848-77. doi: 10.3390/molecules190913848. Molecules. 2014. PMID: 25191874 Free PMC article. Review.
-
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.Drug Resist Updat. 2005 Feb-Apr;8(1-2):15-26. doi: 10.1016/j.drup.2005.02.002. Drug Resist Updat. 2005. PMID: 15939339 Review.
-
ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Pharm Res. 2014 Sep;31(9):2237-55. doi: 10.1007/s11095-014-1389-0. Epub 2014 May 20. Pharm Res. 2014. PMID: 24842659 Review.
-
Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.Eur J Med Chem. 2017 Dec 15;142:271-289. doi: 10.1016/j.ejmech.2017.07.062. Epub 2017 Aug 3. Eur J Med Chem. 2017. PMID: 28851502 Review.
Cited by
-
The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide.Cancers (Basel). 2020 Jul 19;12(7):1963. doi: 10.3390/cancers12071963. Cancers (Basel). 2020. PMID: 32707710 Free PMC article.
-
Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.Theranostics. 2021 Apr 19;11(13):6334-6354. doi: 10.7150/thno.59342. eCollection 2021. Theranostics. 2021. PMID: 33995661 Free PMC article. Review.
-
Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.Medicine (Baltimore). 2017 Nov;96(45):e8570. doi: 10.1097/MD.0000000000008570. Medicine (Baltimore). 2017. PMID: 29137078 Free PMC article.
-
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.Int J Mol Sci. 2017 Sep 7;18(9):1926. doi: 10.3390/ijms18091926. Int J Mol Sci. 2017. PMID: 28880238 Free PMC article. Review.
-
Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line.J Cancer. 2017 Sep 16;8(16):3287-3295. doi: 10.7150/jca.19426. eCollection 2017. J Cancer. 2017. PMID: 29158802 Free PMC article.
References
-
- Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–5557. - PubMed
-
- Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–365. - PubMed
-
- Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist. 2003;8:531–538. - PubMed
-
- Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971–979. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources